Everest Medicines grants employee share options and awards

Everest Medicines Limited announced grants of 74,000 share options and 234,800 share awards to employees on October 2, 2025. The options were granted to three individuals under the Post-IPO Share Option Scheme at an exercise price of HK$57.50, matching the market price of the shares on the grant date. These options have a seven-year exercise period and will vest equally over four years from various commencement dates between July 2, 2025, and September 1, 2025.

Additionally, 234,800 awards were granted to 19 Award Grantees under the Pre-IPO ESOP. These awards, with no purchase price, also reflect a market price of HK$57.50 per share on the grant date. Similar to the options, these awards will vest equally over four years from commencement dates ranging from April 1, 2025, to September 29, 2025.

The grants aim to attract, retain, incentivize, and reward employees, aligning their interests with the company's and encouraging them to enhance shareholder value. No performance targets are attached to either the options or awards, a decision the remuneration committee deems market competitive and consistent with the company’s remuneration policy.